Bayer has recently opened its latest life science incubator, Bayer Co.Lab Berlin, strategically positioned on the Global Headquarters Campus of its Pharmaceuticals Division. This facility is proximal to prominent research and clinical institutions. MyoPax GmbH, a Berlin-based enterprise known for its muscle regeneration therapies and associated with Charité Universitätsmedizin and the Max-Delbrück-Center of the Helmholtz Association, has become the first business to occupy the new premises.
Bayer Co.Lab Berlin is a new addition to the company’s worldwide network of life science incubators, which is situated in major innovation centers such as Cambridge (USA), Kobe (Japan), and Shanghai (China). This incubator offers modern laboratories, cooperative workspaces, and specialized support for startups, contributing significantly to the promotion of local innovations at the heart of Berlin.
“Biotechnology is incredibly vital to the progressive evolution of Berlin’s pharmaceutical and healthcare realm. The introduction of Bayer Co.Lab in Berlin helps bridge science and industry, bringing us closer to our mutual aim of accelerating the development of drugs and medical solutions,” expressed Kai Wegner, Governing Mayor of Berlin. “The Berlin Co.Lab launch is a key component of our initiative to establish Berlin as a leading hub for the healthcare sector in Germany. I extend gratitude to Bayer AG for their valuable collaboration and their trust in Berlin as a hub for science and innovation.”
Juergen Eckhardt, MD, who leads business development and licensing at Bayer Pharmaceuticals, remarked, “Creating Bayer Co.Lab Berlin marks a notable milestone in Bayer’s external innovation agenda. It’s geared towards fostering collaboration within the biotech sphere. Complementary to the future Berlin Center for Gene and Cell Therapies, this incubator provides a springboard for Europe’s leading scholars and innovators, enhancing Berlin’s life sciences landscape.”
Bayer’s global bespoke incubator network offers extensive support for startups to translate their visions into practice. Entrepreneurs joining Bayer Co.Lab Berlin will gain access to an advanced facility, a worldwide community of collaborative thinkers, insights from Bayer’s specialists in various fields, and sustained connectivity with ecosystem partners. This structured support ensures startups evolve in a nurturing environment, rapidly advancing towards their clinical goals.
“We are thrilled to be the pioneering resident company at Bayer Co.Lab Berlin,” expressed Verena Schoewel-Wolf, CEO of MyoPax. “This space will not only supply us with cutting-edge lab facilities but also access to Bayer’s domestic and international R&D expertise, manufacturing, regulatory, and more to advance our mission of effective muscle therapy innovations with our unique muscle stem cell technology.”
Projected to open fully by 2028, the Berlin Center for Gene & Cell Therapies will offer unique European infrastructure that includes state-of-the-art incubators and production facilities, ensuring Bayer Co.Lab’s prominent role in the ecosystem, supporting resident companies’ expansion.
Bayer Co.Lab is an innovative life science incubator network worldwide, committed to pioneering scientific progress and breakthroughs. Residing in strategic locales such as Berlin, Cambridge, Kobe, and Shanghai, Bayer Co.Lab seamlessly integrates novice entrepreneurs with exclusive expertise, resources, and international networks—without entanglements.
Bayer, a global leader with fundamental proficiencies in healthcare and nutrition sciences, dedicates to their guiding principle, “Health for all, Hunger for none.” Their offerings are crafted to aid both individuals and our planet to flourish, tackling significant issues posed by the increasing, aging global populace.